Delivery Order SPE2DB20D1100-SPE2DB25FE1T6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for Testopel 75 mg pellets valued at $10,289.00. This delivery order, issued on August 25, 2025, represents a firm fixed price contract with performance expected to conclude by September 16, 2025. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established capability to...
- The Defense Logistics Agency awarded a delivery order valued at $4,115.60 to AmerisourceBergen Drug Corp for the supply of Testopel 75 mg pellets (10-count units). This firm fixed-price delivery order, issued on April 23, 2025, with an ultimate completion date of May 14, 2025, represents a non-competitive procurement under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a $2,057.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Testopel 75 mg pellets (10 count) on October 16, 2025, with completion targeted for November 6, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $8,231.20 to AmerisourceBergen Drug Corp for the supply of Testopel 75 mg pellets (10 units) on September 17, 2025. This competitive, firm fixed-price delivery order is scheduled for completion by October 8, 2025, with fulfillment based at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $2,057.80 to AmerisourceBergen Drug Corp for Testopel 75 mg pellets on June 11, 2025, with a completion date of July 3, 2025. This firm fixed price delivery order represents a non-competitive set-aside transaction and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Testopel is a testosterone replacement therapy product used in hormone treatment applications within military and federal healthcare...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the supply of TESTOPEL 75 MG PELLETS 100S. The contract has a firm fixed price ceiling value of $11,934.27 and an ultimate completion date of August 2, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued up to $999,999,999.00 through...
- The Defense Logistics Agency awarded a $3,978.08 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 100 units of Testopel 75 mg pellets. Amerisourcebergen Drug Corporation will deliver the pellets to a location in Conshohocken, Pennsylvania under the terms of the order. As the prime contractor, Amerisourcebergen Drug Corporation is a division of Amerisourcebergen Corporation. The delivery order was issued on August 15, 2023 and has a period of performance...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 100 units of TESTOPEL 75 MG PELLETS. The order, valued at $3,978.09, is to be completed by January 26, 2024. Amerisourcebergen Drug Corp is a prime contractor that has received multiple awards from DLA Troop Support Medical to supply pharmaceuticals, medical supplies, and related distribution services in support of...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at approximately $4,000 to Amerisourcebergen Drug Corporation for the supply of 100 units of Testopel 75 mg pellets. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a period of three weeks concluding in early September. As a major supplier of pharmaceuticals to the Department of Defense, this order for testosterone replacement therapy supports DLA's provision of medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,978.09 fixed-price delivery order is for the supply of TESTOPEL 75 MG PELLETS 100S, a medical product, with a completion date of November 25, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1T6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,346.74 to AmerisourceBergen Drug Corp for the supply of Testopel 75 mg pellets (100-count units) with a completion date of September 11, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and is classified as a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major healthcare distributor. This award is issued under AmerisourceBergen's broader $999.999 billion IDC with DLA designated as SPE2DX, which runs through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen's status as a prime vendor for federal medical procurement reflects its established capability to meet DLA requirements through open competition, supplying specialty medications, brand-name and generic drugs, and other critical medical commodities across multiple therapeutic domains to support the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.3k | 8/20/25 |